Virtus ETF Advisers’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Virtus ETF Advisers’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-936	Closed	-$100K	–	492
2023 Q1	$100K	Sell	936 -353	-27%	-$40.6K	0.06%	338
2022 Q4	$142K	Sell	1,289 -2,895	-69%	-$188K	0.07%	360
2022 Q3	$247K	Buy	4,184 +32	+0.8%	+$1.46K	0.1%	292
2022 Q2	$117K	Sell	4,152 -737	-15%	-$21.4K	0.04%	393
2022 Q1	$185K	Sell	4,889 -282	-5%	-$11.1K	0.08%	203
2021 Q4	$204K	Sell	5,171 -3,872	-43%	-$121K	0.08%	201
2021 Q3	$214K	Sell	9,043 -476	-5%	-$11.2K	0.09%	254
2021 Q2	$234K	Buy	+9,519	New	+$212K	0.1%	233

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Virtus ETF Advisers's RXDX Position: Q2 2023 in Review

Virtus ETF Advisers sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 936 shares — an estimated $100K sold.

Virtus ETF Advisers first reported a position in RXDX in Q2 2021 and held it in 8 quarters. The position peaked at $247K in Q3 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Virtus ETF Advisers reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Virtus ETF Advisers sold 936 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $100K.
Virtus ETF Advisers first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Virtus ETF Advisers's Prometheus Biosciences, Inc. Common Stock position peaked at $247K in Q3 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Virtus ETF Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.